



January 9, 2024

**CARDIOCOMM SOLUTIONS, INC.  
FOR IMMEDIATE RELEASE**

**CARDIOCOMM SOLUTIONS APPOINTS NEW CFO**

**TORONTO, ONTARIO** - CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm” or the “Company”), a global medical provider of consumer heart monitoring and medical electrocardiogram (“ECG”) software solutions, is pleased to announce the appointment of Mr. Robert Caines as Chief Financial Officer (“CFO”) of the Company.

Effective January 8, 2024, Mr. Caines assumed the role of CFO, replacing Mr. Etienne Grima who served as interim CFO since August 3, 2023. Mr. Caines will also continue to serve as Chairman of the Board of Directors and Mr. Grima will continue to serve as the Company’s Chief Executive Officer.

The Company also announces that it has issued 250,000 stock options to Etienne Grima, the Company’s CEO, in accordance with his employment agreement. The options are exercisable at \$0.05 per share for five years from the date of grant and vest immediately. The grant is subject to the provisions of the Company’s Stock Option Plan, the policies of the TSX Venture Exchange and applicable securities laws.

To learn more about CardioComm’s products and for further updates please visit the Company’s websites at [www.cardiocommsolutions.com](http://www.cardiocommsolutions.com) and [www.theheartcheck.com](http://www.theheartcheck.com).

**About CardioComm Solutions**

CardioComm Solutions’ patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485 and ISO 27001 certifications, is HIPAA compliant and holds medical device clearances and sales licenses from the USA (FDA) and Canada (Health Canada).

**FOR FURTHER INFORMATION PLEASE CONTACT:**

Etienne Grima, Chief Executive Officer

1-877-977-9425 x227

[investor.relations@cardiocommsolutions.com](mailto:investor.relations@cardiocommsolutions.com)

**Forward-looking statements**

This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management’s current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.

In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (*Continuous Disclosure Obligations*).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.